Esperite (ESP) with The Cell Factory has confirmed a long-term effect of extracellular vesicle drug candidate CF-MEV-132 for the treatment of Bronchopulmonary Dysplasia.

February 27, 2019 Group News

CF-MEV-132 drug candidate belongs to the CF-MEV family of anti-inflammatory EV drugs produced by The Cell Factory

Amsterdam, The Netherlands – 27 February 2019
read more

ESPERITE NV (ESP) AND PBKM (FAMICORD GROUP) SIGN EXCLUSIVE AGREEMENT REGARDING POTENTIAL ACQUISITION OF CRYO-SAVE’S FAMILY STEM CELL BANKING BUSINESS.

February 22, 2019 Group News

ESPERITE NV (ESP) AND PBKM (FAMICORD GROUP) SIGN EXCLUSIVE AGREEMENT REGARDING POTENTIAL ACQUISITION OF CRYO-SAVE’S FAMILY STEM CELL BANKING BUSINESS.

Amsterdam, the Netherlands – 22 February 2019
read more

Esperite (ESP) with The Cell Factory, prepares to raise series A round of investments to continue its clinical program testing Extracellular Vesicles drug candidates.

November 29, 2018 Group News

This investments would put the Company at the pole position on the market with its four Extracellular Vesicles drug candidates for Crohn’s, Bronchopulmonary dysplasia, Epilepsy and Stroke

Amsterdam, The Netherlands – 29 November 2018
read more

Page 1 of 3912345...102030...Last »